CUE BIOPHARMA INC's ticker is CUE and the CUSIP is 22978P106. A total of 65 filers reported holding CUE BIOPHARMA INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $24,000 | +200.0% | 10,323 | +381.3% | 0.00% | – |
| Q2 2023 | $8,000 | – | 2,145 | +879.5% | 0.00% | – |
| Q3 2022 | $0 | – | 219 | +995.0% | 0.00% | – |
| Q2 2022 | $0 | -100.0% | 20 | -99.2% | 0.00% | – |
| Q1 2022 | $13,000 | -82.9% | 2,660 | -60.3% | 0.00% | – |
| Q4 2021 | $76,000 | +81.0% | 6,699 | +135.0% | 0.00% | – |
| Q3 2021 | $42,000 | +75.0% | 2,851 | +39.8% | 0.00% | – |
| Q2 2021 | $24,000 | -11.1% | 2,039 | -8.5% | 0.00% | – |
| Q1 2021 | $27,000 | +800.0% | 2,229 | +998.0% | 0.00% | – |
| Q4 2020 | $3,000 | +200.0% | 203 | +322.9% | 0.00% | – |
| Q3 2020 | $1,000 | 0.0% | 48 | +17.1% | 0.00% | – |
| Q2 2020 | $1,000 | -50.0% | 41 | -62.7% | 0.00% | – |
| Q1 2020 | $2,000 | -92.3% | 110 | -93.3% | 0.00% | – |
| Q4 2019 | $26,000 | 0.0% | 1,637 | -41.7% | 0.00% | – |
| Q3 2018 | $26,000 | -50.0% | 2,808 | -34.8% | 0.00% | – |
| Q2 2018 | $52,000 | – | 4,305 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Prosight Management, LP | 1,510,282 | $7,370,000 | 4.76% |
| SANDERS MORRIS HARRIS LLC | 873,021 | $4,261,000 | 0.83% |
| P.A.W. CAPITAL CORP | 150,000 | $732,000 | 0.76% |
| Nantahala Capital Management | 2,244,359 | $10,952,000 | 0.48% |
| Bleichroeder LP | 552,000 | $2,694,000 | 0.48% |
| APOGEM CAPITAL LLC | 111,259 | $543,000 | 0.37% |
| Slate Path Capital LP | 1,483,619 | $7,240,000 | 0.37% |
| Robertson Stephens Wealth Management, LLC | 478,500 | $2,335,000 | 0.20% |
| CARLSON CAPITAL L P | 405,000 | $1,976,000 | 0.14% |
| Bridgefront Capital, LLC | 19,968 | $97,000 | 0.12% |